Related Experiment Video
Updated: Aug 19, 2026
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Serum concentrations of soluble ICAM-1 and VCAM-1 in patients with colorectal cancer. Clinical implications
K Giannoulis1, C Angouridaki, G Fountzilas
13rd Department of Surgery, AHEPA University Hospital, Thessaloniki, Greece. kgiann@med.auth.gr
Background:
In colorectal cancer (CRC), serum levels of adhesion molecules ICAM-1 and VCAM-1 increase with progressing disease. Our aim was to investigate the effect of treatment in serum ICAM-1 and VCAM-1.
Methods:
Serum levels of ICAM-1 and VCAM-1 were determined in 154 patients with CRC. Patients with non-metastatic disease had been treated with "curative" resections, and those with advanced disease were receiving chemotherapy. A group of 48 healthy blood donors served as control. Serum concentrations ranging 2SD above and below the controls median were accepted as "normal".
Results:
Significantly more patients with advanced disease demonstrated high serum ICAM-1 and VCAM-1 (p<0.001, p=0.043 respectively). However, in some of them serum ICAM-1 and VCAM-1 were below "normal".
Conclusions:
Serum ICAM-1 and VCAM-1 may be valuable markers of residual or biologically aggressive disease after curative resections. In advanced disease, they could be useful predictors of response to chemotherapy.
More Related Videos
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
07:32Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software
Published on: April 12, 2024
